dihexa fda approval status 2026 Undercutting HHS Secretary Robert F. Kennedy Jr.'s recent push to Semax Legal Status 2026: FDA

5 mg Vial Protocol (3 mL = ~1.67 mg/mL) Reconstitution: Add 3.0 mL bacteriostatic water ~1.67 mg/mL concentration

"Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity"

CagriSema treatment resulted in substantially greater and clinically meaningful weight loss (-20.4%) than semaglutide alone (-14.9%), cagrilintide alone (-11.5%), or placebo (-3.0%), a finding consistent with at least partial additivity, although the study design does not permit a formal assessment of additive or synergistic effects

Finished-Product Testing Stability should be evaluated in the actual formulation rather than assumed from a raw-material report